
ASH 23 Posters
GTC presented abstracts at ASH 2023 GTC’s posters from 2023 Convention of American Society of Hematology are now available to be downloaded. Please reach out
GTC presented abstracts at ASH 2023 GTC’s posters from 2023 Convention of American Society of Hematology are now available to be downloaded. Please reach out
Early cancer detection diagnostic companies have received a lot of attention and venture capital investment over the last few years with numerous labs launching diagnostic tests to address this potentially massive market. While the realized clinical value of these tests for patients is still some way off, many companies have started enrollment in clinical studies and are building databases to advance this technology.
Homologous recombination deficiency (HRD) is the hallmark of breast cancer gene 1/2 (BRCA1/2)-mutated tumors and the unique biomarker for predicting response to double-strand break (DSB)–inducing drugs. The demonstration of HRD in tumors with mutations in genes other than BRCA1/2 is considered the best biomarker of potential response to these DSB-inducer drugs.
GTC presented abstracts at ASCO 2023 GTC’s posters from 2023 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
Irvine, California– May 31, 2023 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology
GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
GTC presented abstracts at AACR 2023 GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach
Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with Artificial Intelligence Irvine, California– April
GTC was recently published in the Journal of Medical Artificial Intelligence – Accuracy of predicting IgHV mutation status in chronic lymphocytic leukemia using RNA expression profiling and machine learning.
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative